文献速递多重用药老年慢病共病管理

多重用药对老年人及小鼠炎症谱影响的比较:转化衰老研究启示

Comparing Effects of Polypharmacy on Inflammatory Profiles in Older Adults and Mice: Implications for Translational Aging Research.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2022-01-01

基于Concord健康与老龄化男性项目5年随访的横断面分析,比较多重用药(≥5种药物)与社区居住≥70岁男性27种血清细胞因子的关联,并在健康衰老小鼠中验证。老年人多重用药与IL-8、CCL3等炎症因子升高相关,而小鼠中未见差异,提示炎症标志物可能与 underlying diseases 相关而非多重用药本身。

要点

  • 老年人多重用药(≥5种药物)与IL-8、CCL3等炎症因子升高相关。
  • 健康衰老小鼠接受多重用药后炎症谱无显著差异。
  • 药物负担指数(DBI)未影响多重用药与炎症的关联。

核心结论

  • 老年人多重用药与部分炎症标志物升高相关,但健康衰老小鼠中未见此关联。

研究设计与样本

  • 对Concord健康与老龄化男性项目5年随访数据做横断面分析,纳入社区居住≥70岁男性,多重用药组409例,非多重用药组495例。
  • 用多重免疫分析法测27种血清细胞因子,多变量线性回归校正年龄、衰弱、共病和个体药物类别。
  • 在衰老雄性小鼠中给予长期多重用药或对照,检测23种细胞因子血清水平。

主要发现

  • 多重用药组IL-8、IL-6、CCL3、Eotaxin、IL-1ra、IL-1β、IP-10浓度显著高于非多重用药组,抗炎因子IL-4浓度较低。
  • 完全校正模型中,多重用药与IL-8和CCL3浓度正相关。
  • 对照与多重用药小鼠的炎症谱无显著差异。
  • DBI在男性或小鼠中均未影响上述关系。

关键数值与推荐

  • 多重用药定义为≥5种药物。
  • 老年人多重用药与IL-8、CCL3正相关(完全校正多变量模型)。
  • 老年男性多重用药组(n=409)与非多重用药组(n=495)比较,部分细胞因子浓度差异显著。

临床怎么用

  • 老年共病患者多重用药时,可关注IL-8、CCL3等炎症标志物,但需结合共病情况解释。
  • 健康衰老小鼠模型未重现老年人多重用药相关炎症改变,提示转化研究需考虑疾病背景。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aging and multimorbidity are associated with inflammation. Polypharmacy is common in older people with multimorbidity. Given the potential for interactions between polypharmacy and inflammation, the relationship between inflammation and polypharmacy were studied in older adults with multimorbidity and in healthy aging mice. A cross-sectional analysis of data from the 5-year wave of the Concord Health and Ageing in Men Project, a population-based study of community-dwelling men aged ≥70 years. Serum concentrations of 27 cytokines were measured using a multiplex immunoassay. Associations between polypharmacy (≥5 medications) and cytokines were evaluated using multivariable linear regression adjusting for age, frailty, comorbidities, and individual drug classes. Interaction between polypharmacy and Drug Burden Index (DBI-drugs with anticholinergic and sedative effects) was analyzed. Effects of polypharmacy and DBI on serum levels of 23 cytokines were determined in aging male mice treated with chronic polypharmacy or control. Compared to the nonpolypharmacy group (n = 495), CHAMP participants with polypharmacy (n = 409) had significantly higher concentrations of IL-8, IL-6, CCL3, Eotaxin, IL-1ra, IL-1β, IP-10, and lower concentrations of anti-inflammatory cytokine IL-4. In fully-adjusted multivariable models, polypharmacy was positively associated with concentrations of IL-8 and CCL3. There were no significant differences in inflammatory profiles between control and polypharmacy-treated mice. The relationship was not influenced by DBI in men or in mice. Inflammatory markers associated with polypharmacy in older adults were not seen in healthy aged mice administered polypharmacy, and may be related to underlying diseases. The polypharmacy mouse model provides opportunities for mechanistic investigations in translational research.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Wu H, Mach J, Gnjidic D, et al. Comparing Effects of Polypharmacy on Inflammatory Profiles in Older Adults and Mice: Implications for Translational Aging Research. J Gerontol A Biol Sci Med Sci. 2022. PMID: 35299251. doi:10.1093/gerona/glac061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。